4DMedical Issues New Shares Under Incentive Plan and Confirms Regulatory Compliance

4DMedical Ltd ( (AU:4DX) ) has shared an update.

4DMedical has issued 485,976 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan, expanding its share base in line with previously established employee and executive remuneration structures. The company confirmed that the shares were issued without a prospectus under the Corporations Act and stated it is fully compliant with its financial reporting and continuous disclosure obligations, with no undisclosed price-sensitive information identified at the time of the notice.

This step reinforces 4DMedical’s use of equity-based incentives to retain and motivate key staff while signalling ongoing adherence to governance and regulatory standards. The absence of excluded information and the formal cleansing notice support the shares’ tradability on the market and provide assurance to existing and prospective shareholders regarding transparency and regulatory compliance.

The most recent analyst rating on (AU:4DX) stock is a Hold with a A$4.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

More about 4DMedical Ltd

4DMedical Limited is an Australian medical technology company focused on lung health, developing imaging and diagnostic solutions for respiratory conditions. The company is listed on the ASX under the ticker 4DX and operates in both Australia and the United States, targeting clinical and research markets in advanced pulmonary imaging.

Average Trading Volume: 6,812,628

Technical Sentiment Signal: Buy

Current Market Cap: A$2.17B

See more insights into 4DX stock on TipRanks’ Stock Analysis page.